SERENA-4 is an ongoing randomized multicenter, double-blind phase III trial comparing the safety and efficacy of camizestrant plus palbociclib vs. anastrozole plus palbociclib in patients with ER+/HER2− previously untreated breast cancer [43]. The gene discussed is ESR1; the disease is breast carcinoma.